Selvita S.A.

Warsaw Stock Exchange SLV.WA

Selvita S.A. Capital Expenditure for the year ending December 31, 2023: USD -18.75 M

Selvita S.A. Capital Expenditure is USD -18.75 M for the year ending December 31, 2023, a 19.14% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Selvita S.A. Capital Expenditure for the year ending December 31, 2022 was USD -23.19 M, a -240.50% change year over year.
Selvita S.A. Capital Expenditure for the year ending December 31, 2021 was USD -6.81 M, a -69.52% change year over year.
Selvita S.A. Capital Expenditure for the year ending December 31, 2020 was USD -4.02 M, a -1,152.81% change year over year.
Selvita S.A. Capital Expenditure for the year ending December 31, 2019 was USD -320.63 K, a 84.55% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Warsaw Stock Exchange: SLV.WA

Selvita S.A.

CEO	Mr. Boguslaw Stanislaw Sieczkowski M.B.A.
IPO Date	Oct. 17, 2019
Location	Poland
Headquarters	ul. Bobrzynskiego 14
Employees	886
Sector	Healthcare
Industries Biotechnology Big Data Chemicals & Advanced Materials Clinical Trials Database Petrochemicals Pharmaceuticals Research & Consulting

Description

Selvita S.A. operates as a contract research organization in Poland, rest of Europe, the United States, and internationally. It operates in two segments, Contract Research Organization (CRO) services, and Bioinformatics. The company offers drug discovery services in the areas of assay development and screening, medicinal and synthetic chemistry, computer-aided drug design/ artificial intelligence, structural biology, in vitro/ In Vivo pharmacology, ADME/DMPK and analytical testing. It also provides pharma services in the field of drug testing and bioanalytical analysis, including development and optimization, validation and transfer, stability studies, quality control, and regulatory aspects support services. In addition, the company offers research and development services in the areas of process research, laboratory scale custom synthesis of NCEs, industrial chemistry, and synthesis of isotopically labelled compounds, as well as other services for the agrochemical industry. Further, it provides bio-data science and advanced software services to data-driven life science and healthcare organizations. Selvita S.A. was founded in 2007 and is headquartered in Krakow, Poland.

Key trends

Past 5 years